The purpose of this study was to review evidence for the efficacy and safety of cyclosporine therapy in patients with psoriatic arthritis.
Methods
We performed a systematic literature review of available evidence using the electronic database PubMed.
Results
The available evidence suggests that cyclosporine may be an effective third-line treatment for psoriatic arthritis. However, its well-established side effect profile limits long-term use.
Conclusion
Cyclosporine may be an effective treatment option for psoriatic arthritis, but large randomized, placebo-controlled clinical trials with adequate sample sizes are needed to assess its impact on symptomatic control, inhibition of radiological disease progression, prevention of disability, and improvement of quality of life.
HoS., ClipstoneN., TimmermannL.The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol.1996 Sep; 80(3 Pt 2): S40–5.
3.
HernándezG.L., VolpertO.V., IñiguezM.A.Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med.2001 Mar 5; 193(5): 607–20.
4.
LowesM.A., KikuchiT., Fuentes-DuculanJ.Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol.2008 May; 128(5): 1207–11.
5.
SalvaraniC., MacchioniP., OlivieriI.A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol.2001 Oct; 28(10): 2274–82.
6.
PorzioF., AntonelliM., AntonelliS.Cyclosporin A in the long-term treatment of psoriatic arthritis. Br J Rheumatol.1996 Dec; 35(12): 1331.
7.
MacchioniP., BoiardiL., CremonesiT.The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol Int.1998; 18(1): 27–33.
8.
FoxR.I., MorganS.L., SmithH.T., RobbinsB.A., ChocM.G., BaggottJ.E.Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford).2003 Aug; 42(8): 989–94.
9.
SpadaroA., RiccieriV., Sili-ScavalliA., SensiF., TaccariE., ZoppiniA.Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol.1995 Sep-Oct; 13(5): 589–93.
10.
FraserA.D., van KuijkA.W., WesthovensR.A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis.2005 Jun; 64(6): 859–64.
11.
ClarkC.M., KirbyB., MorrisA.D.Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol.1999 Aug; 141(2): 279–82.
12.
GerardsA.H., LandewéR.B., PrinsA.P.Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis.2003 Apr; 62(4): 291–6.
13.
SteinC.M., PincusT., YocumD.Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum.1997 Oct; 40(10): 1843–51.
14.
KorstanjeM.J., van Breda VriesmanC.J., van de StaakW.J.Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol.1990 Aug; 23(2 Pt 1): 320–1.
15.
AydinF., CanturkT., SenturkN., TuranliA.Y.Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol.2006 Jul; 31(4): 520–4.
16.
MohananS., RamassamyS., ChandrashekarL., ThappaD.M.A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis. J Dermatolog Treat.2014 Feb; 25(1): 50–3.
17.
AtzeniF., BoccassiniL., AntivalleM., SalaffiF., Sarzi-PuttiniP.Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis.2011 Apr; 70(4): 712–4.
18.
D'AngeloS., CutroM.S., LubranoE.Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis.2010 May; 69(5): 934–5.
19.
KaranikolasG.N., KoukliE.M., KatsaliraA.Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol.2011 Nov; 38(11): 2466–74.
20.
ChangC.A., GottliebA.B., LizzulP.F.Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol.2011 Sep 13; 7(10): 588–98.
21.
KingsleyG.H., KowalczykA., TaylorH.A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford).2012 Aug; 51(8): 1368–77.
22.
MenterA., KormanN.J., ElmetsC.A.Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol.2009 Sep; 61(3): 451–85.
23.
ZachariaeH.Renal toxicity of long-term cyclosporin. Scand J Rheumatol.1999; 28(2): 65–8.
24.
HughJ., Van VoorheesA.S., NijhawanR.I.The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol.2013 Oct 31.
25.
SaadA.A., SymmonsD.P., NoyceP.R., AshcroftD.M.Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol.2008 May; 35(5): 883–90.
26.
McInnesI.B., KavanaughA., GottliebA.B.; PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet.2013 Aug 31; 382(9894): 780–9.
27.
KavanaughA., RitchlinC., RahmanP.; on behalf of the PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis.2014 Feb 19.
